Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 20/20 | 0.64 |
| ▸ | HTR2B | P41595 | 19/20 | 0.64 |
| ▸ | HTR2A | P28223 | 16/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | HTR6 | P50406 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6582652 | 0.83 | HTR2C (0.56) | HTR2CHTR2BHTR2A | |
| SCHEMBL7361498 | 0.78 | HTR2C (1.00) | HTR2CHTR2BHTR2ANPC1MTOR | |
| Sb-242084 SCHEMBL18953108 | 0.77 | HTR2C (0.97) | HTR2CHTR2BHTR2ANPC1MTOR | |
| Sb-242084 SCHEMBL507945 | 0.77 | HTR2C (1.00) | HTR2CHTR2BHTR2ANPC1MTOR | |
| Sb-242084 SCHEMBL29388888 | 0.77 | HTR2C (1.00) | HTR2CHTR2BHTR2ANPC1MTOR | |
| Sb-242084 SCHEMBL29462298 | 0.77 | HTR2C (1.00) | HTR2CHTR2BHTR2ANPC1MTOR | |
| Sb-242084 SCHEMBL18395254 | 0.76 | HTR2C (0.98) | HTR2CHTR2BHTR2ANPC1MTOR | |
| SCHEMBL2229787 | 0.76 | HTR2C (1.00) | HTR2CHTR2BHTR2ANPC1MTOR | |
| Sb-243213 SCHEMBL31060820 | 0.75 | HTR2C (1.00) | HTR2CHTR2BHTR2ANPC1MTOR | |
| Sb-243213 SCHEMBL677610 | 0.75 | HTR2C (1.00) | HTR2CHTR2BHTR2ANPC1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1146044-B1 | CNS active cyclobuta-indole carboxamide derivatives, processes for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2004-09-01 | — | — | EP | claimed |
| US-6743818-B2 | TREATING ANXIETY, PANIC ATTACKS, OBSESSIVE-COMPULSIVE DISORDERS, PHOBIAS, IMPULSIVE DISORDERS, DRUG ABUSE, COGNITIVE DISORDERS, PSYCHOSES, DEPRESSION AND MOOD DISORDERS | LES LABORATOIRES SERVIER (FR) | 2004-06-01 | — | — | US | claimed |
| US-20030032812-A1 | Cyclobutaindolecarboxamide compounds | PEGLION JEAN-LOUIS (FR) | 2003-02-13 | — | — | US | claimed |
| US-20010044426-A1 | Cyclobutaindolecarboxamide compounds | LES LABORATOIRES SERVIER (FR) | 2001-11-22 | — | — | US | claimed |
| EP-1146044-A1 | CNS active cyclobuta-indole carboxamide derivatives, processes for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-10-17 | — | — | EP | claimed |
| EP-1146044-B1 | CNS active cyclobuta-indole carboxamide derivatives, processes for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2004-09-01 | — | — | EP | disclosed |
| US-6743818-B2 | TREATING ANXIETY, PANIC ATTACKS, OBSESSIVE-COMPULSIVE DISORDERS, PHOBIAS, IMPULSIVE DISORDERS, DRUG ABUSE, COGNITIVE DISORDERS, PSYCHOSES, DEPRESSION AND MOOD DISORDERS | LES LABORATOIRES SERVIER (FR) | 2004-06-01 | — | — | US | disclosed |
| US-20030032812-A1 | Cyclobutaindolecarboxamide compounds | PEGLION JEAN-LOUIS (FR) | 2003-02-13 | — | — | US | disclosed |
| US-6452015-B2 | FOR TREATMENT OF ANXIETY, PANIC ATTACKS, OBSESSIVE-COMPULSIVE DISORDERS, PHOBIAS, IMPULSIVE DISORDERS, DRUG ABUSE, COGNITIVE DISORDERS, PSYCHOSES, DEPRESSION AND MOOD DISORDERS | LES LABORATOIRES SERVIER (FR) | 2002-09-17 | — | — | US | disclosed |
| US-20010044426-A1 | Cyclobutaindolecarboxamide compounds | LES LABORATOIRES SERVIER (FR) | 2001-11-22 | — | — | US | disclosed |
| EP-1146044-A1 | CNS active cyclobuta-indole carboxamide derivatives, processes for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044426-A1 | Cyclobutaindolecarboxamide compounds | HRH4, HTR4, CNR1 | HTR2C 120/4885HTR2B 53/4885HTR2A 248/4885 |
| US-20030032812-A1 | Cyclobutaindolecarboxamide compounds | CYP2W1, HRH4, CNR1 | HTR2C 54/4885HTR2B 23/4885HTR2A 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.